Asia appears to be global center for counterfeit, substandard drugs

06/16/2013 | Economic Times (India), The

Asia, particularly China and India, appears to be the chief source of what the World Health Organization now labels "substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) medicines." The global market for such fake drugs could be in the range of $50 billion to $200 billion, according to several reports, although authorities point out that large pharmaceutical firms, with export markets and reputations to protect, are rarely the problem.

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD